Results 201 to 210 of about 96,147 (311)

Clinical effect of liver cancer resection combined with selective decongestive devascularization in treatment of primary liver cancer complicated by portal hypertension

, 2016
ZHENG Guilong, DING Haihua -, Ding ZhiQing   +2 more
openalex   +2 more sources

Effectiveness of Gel‐immersion Endoscopic Injection Sclerotherapy Under Texture and Color Enhancement Imaging for Esophageal Varices: A Comparison of Variceal Visibility Under Gel With White Light Imaging

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Objective Gel‐immersion endoscopic injection sclerotherapy (GI‐EIS) addresses the technical challenges in intravariceal injection for esophageal varices (EVs). However, gel accumulation may obscure the variceal morphology. Thus, we developed GI‐EIS under texture and color enhancement imaging (TXI) and evaluated its effectiveness.
Tsunetaka Kato, Takuto Hikichi, Jun Nakamura, Minami Hashimoto, Takumi Yanagita, Mitsuru Otsuka, Daiki Nemoto, Rei Suzuki, Mitsuru Sugimoto, Hiroyuki Asama, Kentaro Sato, Hiroshi Shimizu, Kento Osawa, Rei Ohira, Masao Kobayakawa, Hiromasa Ohira   +15 more
wiley   +1 more source

Unmasking portal hypertension: A case of diagnostic distraction by chronic hemoptysis. [PDF]

Int J Surg Case Rep
Ali AO, Abdi MH, Olhayeh HS, Abdillahi ISS, Abdi AA, Moumin HE.   +5 more
europepmc   +1 more source

A Case of Worsened Refractory Ascites due to Prednisolone Administration for Stricture Prevention after Endoscopic Submucosal Dissection for Extensive Early Esophageal Cancer: Case Report and Literature Review

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Endoscopic submucosal dissection (ESD) is widely used for early esophageal cancer, even in patients with liver cirrhosis (LC). Corticosteroids, administered orally or by local injection, are often used to prevent post‐ESD esophageal stricture. However, their safety in patients with decompensated LC and refractory ascites remains unclear. A man
Yuki Tamura, Masanori Sekiguchi, Kaho Honda, Yu Maruyama, Kenta Ito, Makiko Inoue, Mitsuhiko Shibasaki, Daichi Takizawa, Hirotaka Arai, Toshio Uraoka   +9 more
wiley   +1 more source

Future research direction of portal hypertension based on Baveno VII. [PDF]

Chin Med J (Engl)
Luo X, Wang G, Yang L, Hernandez-Gea V.
europepmc   +1 more source

Bridging the Digital Divide: Examining the Role of Digital Health in Nepal's Healthcare Transformation

World Medical &Health Policy, Volume 18, Issue 1, March 2026.
ABSTRACT This systematic review examines the digital health interventions for inclusive and equitable solutions for transforming healthcare access and delivery in Nepal. The research focuses on improving digital health accessibility among marginalized and rural populations of Nepal.
Manoj Kumar Dahal, Gary L. Kreps
wiley   +1 more source

Revisiting the Role of Surgery in Non-cirrhotic Portal Hypertension: An Ambispective Observational Study in a Tertiary Care Centre. [PDF]

Cureus
Girish A, R P, Chidambaranathan S, J R LJ.   +3 more
europepmc   +1 more source

Safety and Efficacy of Anticoagulation Therapy in Paediatric Patients With Solid Tumours or Lymphomas at Risk of Thrombocytopenia: A Retrospective Study

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Background Patients with solid tumours or lymphomas have an increased risk of thromboembolism (TE) and thrombocytopenia. Evidence‐based strategies for anticoagulation therapy (ACT) for patients with thrombocytopenia are limited. We examined the impact of thrombocytopenia on ACT administration and bleeding incidence in children with solid ...
Andrés Felipe Fajardo, Katherine Talpin, Bishal Harry, Uma H. Athale, Anthony K. C. Chan, Mihir D. Bhatt   +5 more
wiley   +1 more source

Evaluation of portal hypertension and prognosis of patients with HIV/HCV co-infection through comtaminated blood product

, 2012
Mitsuhisa Takatsuki, Susumu Eguchi, Akihiko Soyama, Takashi Kanematsu, Kazuhiko Nakao, Takuma Shirasaka, Masahiro Yamamoto, Hiroyuki Gatanaga, Natsuo Tachikawa, Yuki Kugiyama, Hiroshi Yatsuhashi, Takafumi Ichida, Norihiro Kokudo   +12 more
openalex   +2 more sources

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 535-544, February 2026.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod   +18 more
wiley   +1 more source